Mark E. Goldman
- Virology top 1%
- HIV Research and Treatment 9
- Genetics top 1%
- Estrogen and related hormone effects 16
- Reproductive Medicine top 1%
- Infectious Diseases top 2%
- HIV/AIDS drug development and treatment 16
- Toxicology top 1%
-
- Receptor Mechanisms and Signaling 10
-
- Bone health and treatments 9
-
- Analytical Chemistry and Chromatography 6
-
- Hormonal Regulation and Hypertension 6
-
- Neuroscience and Neuropharmacology Research 6
- Co-authors
- Donald P. McDonnellD. P. McDonnellElisabetta VegetoDale E. MaisB W O'MalleyJ. M. HOFFMANJ A O'BrienEmilio A. Emini
- Journals
- Journal of Medicinal Chemistry (12 papers)Endocrinology (8 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)
- Partner nations
- United StatesBelgiumSwitzerland
In The Last Decade
Mark E. Goldman
102 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Virology 759
- Genetics 1.8k
- Reproductive Medicine 510
- Infectious Diseases 879
- Toxicology 155
Countries citing papers authored by Mark E. Goldman
This map shows the geographic impact of Mark E. Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Goldman more than expected).
Fields of papers citing papers by Mark E. Goldman
This network shows the impact of papers produced by Mark E. Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Goldman. The network helps show where Mark E. Goldman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark E. Goldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 117 | |
| 2 | 2006 | 24 | |
| 3 | 2006 | 15 | |
| 4 | 1999 | 42 | |
| 5 | 1998 | 19 | |
| 6 | 1997 | 6 | |
| 7 | 1997 | 153 | |
| 8 | SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo. | 1996 | 11 |
| 9 | 1995 | 5 | |
| 10 | 1994 | 133 | |
| 11 | 1994 | 69 | |
| 12 | 1990 | 3 | |
| 13 | 1990 | 11 | |
| 14 | 1990 | 84 | |
| 15 | 1988 | 20 | |
| 16 | 1988 | 57 | |
| 17 | 1988 | 1 | |
| 18 | 1988 | 11 | |
| 19 | 1988 | 3 | |
| 20 | 1987 | 13 |
About Mark E. Goldman
Mark E. Goldman is a scholar working on Virology, Toxicology and Infectious Diseases, having authored 103 papers that have together received 6.0k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (16 papers), HIV/AIDS drug development and treatment (16 papers), Receptor Mechanisms and Signaling (10 papers), HIV Research and Treatment (9 papers), Bone health and treatments (9 papers), Analytical Chemistry and Chromatography (6 papers), Hormonal Regulation and Hypertension (6 papers) and Neuroscience and Neuropharmacology Research (6 papers). The work is most often cited by research in Virology (759 citations), Genetics (1.8k citations) and Reproductive Medicine (510 citations). Mark E. Goldman has collaborated with scholars based in United States, Belgium and Switzerland. Frequent co-authors include Donald P. McDonnell, D. P. McDonnell, Elisabetta Vegeto, Dale E. Mais, B W O'Malley, J. M. HOFFMAN, J A O'Brien, Emilio A. Emini, William A. Schleif and Joanna Pike. Their work appears in journals such as Journal of Medicinal Chemistry, Endocrinology, Bioorganic & Medicinal Chemistry Letters, Molecular Pharmacology and Drug Metabolism and Disposition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.